# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elvis Presley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML003-SYN
- Date: 2026-10-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Coleman Ashby-Nakagawa, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Four-month review after the tour. **S**

## History of present illness

Mr. Presley returns two weeks after finishing a three-week tour. He kept every weekly video visit on tour. He has taken buprenorphine 16 mg every morning with rare cravings and no other opioid, and diazepam 32 mg a day without withdrawal symptoms; he sleeps about seven hours with CPAP, on 88% of nights, and his Epworth score is 6. His home blood pressure averages 122/78. On tirzepatide 5 mg weekly for five weeks he has had mild nausea once and no constipation, and his weight is 102.6 kg. His bowels open daily or every other day on polyethylene glycol. He has no eye symptoms. He has started walking each morning and eating his main meal before the show. **S**

| Element | Detail |
|---|---|
| Buprenorphine | 16 mg daily; rare cravings; no other opioid |
| Diazepam | 32 mg a day for five weeks; no withdrawal symptoms |
| Weight | 102.6 kg, down 6.4 kg (5.9%) from intake |
| Blood pressure | Home average 122/78 |
| CPAP | 88% of nights; Epworth 6 |
| Liver tests | ALT 44, AST 33, GGT 55 U/L, now normal |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight down |
| Gastrointestinal | Negative | Nausea once; bowels regular |
| Eyes | Negative | No pain, halos or vision change |
| Psychiatric | Negative | PHQ-9 4; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist **S**
- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag **S**
- Polyethylene glycol 3350, 17 g powder in a glass of water once daily **S**
- Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic only **S**
- Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a time **S**
- Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet daily **S**
- Tirzepatide 5 mg/0.5 mL auto-injector, 5 mg under the skin once weekly **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 102.6 kg; BMI 30.6 kg/m². All vital signs are synthetic.

Potassium: 4.3 mmol/L; Creatinine: 1.02 mg/dL; eGFR (CKD-EPI 2021): 96 mL/min/1.73 m²; Hemoglobin A1c: 5.5%; ALT: 44 U/L; AST: 33 U/L; GGT: 55 U/L; PHQ-9: 4; GAD-7: 5. All results are synthetic.

## Change since baseline

- Potassium: 4 mmol/L at baseline, 4.3 mmol/L at this visit **S**
- Creatinine: 1 mg/dL at baseline, 1.02 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 98 mL/min/1.73 m² at baseline, 96 mL/min/1.73 m² at this visit **S**
- Hemoglobin A1c: 5.8% (high) at baseline, 5.5% at this visit **S**
- ALT: 72 U/L (high) at baseline, 44 U/L at this visit **S**
- AST: 52 U/L (high) at baseline, 33 U/L at this visit **S**
- GGT: 78 U/L (high) at baseline, 55 U/L at this visit **S**
- PHQ-9: 8 at baseline, 4 at this visit **S**
- GAD-7: 9 at baseline, 5 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), second of two doses **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 122/78, pulse 70; weight 102.6 kg, BMI 30.6 |
| Neck | Circumference 42 cm |
| Neurological | No tremor or sedation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Opioid use disorder on buprenorphine** (F11.20). In early remission on buprenorphine: no use of other opioids and rare cravings for more than three months. Safety reviewed: no thoughts of suicide or self-harm; naloxone on hand. **S**
   - Continue 16 mg daily without a planned end; visits every four weeks.
   - Counseling continues.
2. **Benzodiazepine use disorder on a diazepam taper** (F13.20). Five weeks at 32 mg without symptoms; the next step is due. **S**
   - Diazepam 30 mg a day (10 mg three times daily); the 2 mg tablets stopped.
   - Further steps of about 10% every four weeks, with CBT.
3. **Hypertension, stage 2** (I10). At target on amlodipine with valsartan, helped by weight loss; potassium and creatinine normal. **S**
   - Continue; consider lowering the dose if weight loss continues and readings fall below 115/75.
4. **Obesity, class 1, with prediabetes** (E66.811). Down 5.9%, with hemoglobin A1c now 5.5% and liver tests normal. **S**
   - Continue tirzepatide 5 mg weekly; increase to 7.5 mg in four weeks if tolerated.
5. **Obstructive sleep apnea on CPAP** (G47.33). Good adherence and normal sleepiness score; weight loss may lower the pressure needed. **S**
   - Continue CPAP; repeat sleep testing if weight loss reaches 10%.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Buprenorphine dose, withdrawal symptoms, cravings and other opioid use | Every four weeks once stable | Completed today | 16 mg daily; no other opioid; rare cravings |
| Survey | Weekly video visits while away | Weekly during engagements and tours | Completed today | All three weekly visits on tour kept at the fixed time |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's prescriptions |
| Laboratory | Urine drug test, including buprenorphine metabolite and fentanyl | At the start of treatment, then about monthly while doses are changing | Completed today | Buprenorphine, norbuprenorphine and benzodiazepines present; no other opioid; fentanyl absent (narrative) |
| Medication safety | Naloxone on hand and people taught to use it | Every visit | Completed today | On hand at home and in the tour bag |
| Medication safety | Diazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper pace | Every two to four weeks during the taper | Completed today | 32 to 30 mg a day (6%) after five weeks at 32 mg; no withdrawal symptoms |
| Survey | Suicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; firearms and medicines locked |
| Survey | Mood (PHQ-9) and anxiety (GAD-7) | At each review | Completed today | PHQ-9 4 (item 9 scored 0); GAD-7 5 |
| Examination | Office and home blood pressure (target below 130/80) | Every visit | Completed today | Office 122/78; home average 122/78 |
| Laboratory | Potassium and creatinine after starting an angiotensin receptor blocker | Two to four weeks after starting, then every six months | Completed today | Potassium 4.3, creatinine 1.02 |
| Laboratory | Hemoglobin A1c in prediabetes | Every three to six months during treatment | Completed today | 5.5%, from 5.8% |
| Laboratory | Liver tests (ALT, AST, GGT) | Three to six months after an abnormal result | Completed today | ALT 44, AST 33, GGT 55 U/L, all normal, from 72, 52 and 78 |
| Examination | Weight and BMI | Every visit | Completed today | 102.6 kg, BMI 30.6; down 6.4 kg |
| Medication safety | Tirzepatide tolerance: nausea, vomiting, constipation, abdominal pain | At each dose step | Completed today | 5 mg for five weeks: nausea once; no vomiting or constipation |
| Survey | CPAP adherence (device data) and sleepiness (Epworth, recorded as narrative) | Within the first 30 to 90 days, then at each review | Completed today | 88% of nights; Epworth 6 |
| Self-management | Bowel frequency, straining and alarm features | Every visit | Completed today | Daily or every other day |
| Examination | Glaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-up | Every visit; ophthalmology every three to six months while recently controlled | Completed today | No eye symptoms; drops nightly; next ophthalmology visit in three to six months |

## Goal progress

- Stop full-agonist opioids and stabilize on buprenorphine without significant withdrawal. Outcome by 2026-08-07: Buprenorphine 16 mg a day since the consultation; no withdrawal after the first day; cravings low. **S**
- One prescriber and one pharmacy for all controlled medicines. Outcome by 2026-09-23: Monitoring program shows only this clinic's prescriptions since intake. **S**
- Lower the diazepam dose slowly, 5 to 10% every two to four weeks, toward stopping. Outcome by 2026-10-28: 40 mg a day after the alprazolam was combined into it, to 30 mg at four months; no withdrawal symptoms; taper continuing. **S**
- Home blood pressure below 130/80. Outcome by 2026-08-07: Home average 146/94 to 126/80 on amlodipine and valsartan. **S**
- Lose 5% or more of body weight. Outcome by 2026-10-28: 109.0 to 102.6 kg (5.9%) on tirzepatide, with more activity and earlier meals. **S**
- CPAP on at least 70% of nights for four hours or more, with less daytime sleepiness. Outcome by 2026-10-28: CPAP on 88% of nights; Epworth 14 to 6. **S**
- A bowel movement at least every two days without straining. Outcome by 2026-08-07: Every one to two days on buprenorphine and polyethylene glycol. **S**

## Medication changes

- Stopped: Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg) **S**

## Guideline basis

- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recomm Rep 2022;71(3):1-95)
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (J Addict Med 2020;14(2S Suppl 1):1-91)
- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025), American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity (2022), American Gastroenterological Association (Gastroenterology 2022;163(5):1198-1225)
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (2024), N Engl J Med 2024;391(13):1193-1205
- Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline (2019), American Academy of Sleep Medicine (J Clin Sleep Med 2019;15(2):335-343)
- CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs (2026), Aether Forge

## Follow-up

- Second hepatitis B vaccine dose given today. Review in four weeks with the next taper step; influenza vaccine then. **S**

